Aequus Pharmaceuticals Inc. (AQSZF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aequus Pharmaceuticals Inc. (AQSZF) trades at $0.00 with AI Score 59/100 (Grade B). Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing drugs in neurology, ophthalmology, and transplantation. Market cap: $145,898, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for AQSZF: AQSZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AQSZF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AQSZF: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Aequus Pharmaceuticals Inc. (AQSZF) Healthcare & Pipeline Overview
Aequus Pharmaceuticals Inc., based in Canada, specializes in developing and commercializing drugs for neurology, ophthalmology, and transplantation. With products like Vistitan and Evolve, alongside a pipeline of extended-release and cannabinoid-based therapies, Aequus operates in the competitive specialty pharmaceutical market, collaborating with partners like Sandoz and Supernus.
What Is the Investment Thesis for AQSZF?
Aequus Pharmaceuticals operates in niche healthcare markets, offering potential for growth through its existing product portfolio and development pipeline. The company's focus on ophthalmology, neurology, and transplantation provides diversification. Key value drivers include successful commercialization of pipeline products like Topiramate XR and AQS1304, expansion of existing product sales, and strategic partnerships. However, the company's negative profit margin of -71.5% and small market capitalization present risks. Investors should monitor the progress of clinical trials, regulatory approvals, and the company's ability to achieve profitability. The company's beta of -0.28 suggests low volatility relative to the market.
Based on FMP financials and quantitative analysis
AQSZF Key Highlights
- Aequus Pharmaceuticals focuses on specialty pharmaceuticals within neurology, ophthalmology, and transplantation.
- The company markets Vistitan for glaucoma, addressing a significant market need.
- Aequus has a development pipeline including extended-release anti-epileptic drugs and cannabinoid-based therapeutics.
- The company maintains strategic collaborations with Sandoz, Supernus, and Medicom Healthcare.
- Aequus Pharmaceuticals has a gross margin of 53.3% indicating potential profitability from its products.
Who Are AQSZF's Competitors?
AQSZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| NPNKF Nippon Shinyaku Co., Ltd. | $32.75 | +4.30% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AQSZF's Key Strengths?
- Focus on niche therapeutic areas.
- Existing product portfolio with established revenue streams.
- Strategic partnerships with larger pharmaceutical companies.
- Development pipeline of new products.
What Are AQSZF's Weaknesses?
- Small market capitalization.
- Negative profit margin.
- Limited geographic reach.
- Reliance on partnerships for distribution.
What Could Drive AQSZF Stock Higher?
- Clinical trial results for Topiramate XR and Oxcarbazepine XR extended-release tablets for epilepsy.
- Regulatory approval decisions for AQS1303 for the treatment of nausea and vomiting of pregnancy.
- Potential new partnerships for distribution or co-development of products.
- Expansion of the Evolve dry eye product line into new markets.
- Continued growth in sales of Vistitan for glaucoma.
What Are the Key Risks for AQSZF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for development-stage products.
- Regulatory delays or rejections for new product approvals.
- Increased competition from larger pharmaceutical companies.
- Pricing pressures and generic drug penetration.
- Dependence on partnerships for distribution and commercialization.
What Are the Growth Opportunities for AQSZF?
- Expansion of Ophthalmology Product Line: Aequus can expand its Evolve dry eye product line and Vistitan sales by targeting a larger market share within the growing ophthalmology sector. The global dry eye syndrome market is projected to reach $6.5 billion by 2028, offering a substantial opportunity for Aequus to increase revenue through innovative formulations and expanded distribution channels. This expansion can be realized within the next 2-3 years through strategic marketing and partnerships.
- Advancement of Epilepsy Pipeline: The development and commercialization of Topiramate XR and Oxcarbazepine XR extended-release oral tablets for epilepsy represent a significant growth opportunity. The global epilepsy market is expected to reach $11 billion by 2027. Successful clinical trials and regulatory approvals could position Aequus to capture a portion of this market, potentially generating substantial revenue streams starting in 2028.
- Commercialization of Cannabinoid Therapeutics: Aequus's AQS1304, a cannabinoid-based therapeutic for neurological disorders, presents a novel growth avenue. The increasing acceptance of cannabinoid-based therapies for various neurological conditions offers a promising market. The global cannabinoid market is projected to reach $47 billion by 2027. Aequus could potentially launch this product within the next 3-5 years, pending regulatory approvals and clinical trial outcomes.
- Strategic Partnerships and Collaborations: Aequus can leverage strategic partnerships to expand its market reach and product portfolio. Collaborations with companies like Sandoz and Supernus have already proven beneficial. Seeking additional partnerships for distribution, co-development, or licensing agreements can accelerate growth and reduce risk. These partnerships can be forged within the next 1-2 years, enhancing Aequus's market presence and innovation capabilities.
- Geographic Expansion Beyond Canada: While currently focused on the Canadian market, Aequus can explore opportunities for geographic expansion into other regions, such as the United States or Europe. This expansion could involve partnering with local distributors or establishing a direct presence. The global pharmaceutical market offers vast opportunities, and strategic geographic expansion can significantly increase Aequus's revenue base over the next 3-5 years.
What Opportunities Does AQSZF Have?
- Expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Acquisition of new products or technologies.
- Increased demand for specialty pharmaceuticals.
What Threats Does AQSZF Face?
- Competition from larger pharmaceutical companies.
- Regulatory challenges and delays.
- Pricing pressures and generic drug penetration.
- Clinical trial failures.
What Are AQSZF's Competitive Advantages?
- Specialty Focus: Niche therapeutic areas provide less competition.
- Product Portfolio: Diversified product offerings across multiple therapeutic areas.
- Strategic Partnerships: Collaborations with established pharmaceutical companies.
- Development Pipeline: Pipeline of new products in development.
What Does AQSZF Do?
Aequus Pharmaceuticals Inc., established in 2013 and headquartered in Vancouver, Canada, is a specialty pharmaceutical company dedicated to the development and commercialization of differentiated products. The company focuses on addressing unmet needs in neurology, ophthalmology, and transplantation. Aequus markets Vistitan, an ophthalmology product used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It also offers Tacrolimus IR, an immunosuppressant used to prevent acute rejection following organ transplantation, and the Evolve line of dry eye products. In addition to its marketed products, Aequus has a pipeline of development-stage products, including Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. The company is also developing AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy, and AQS1304, a cannabinoid-based therapeutic for neurological disorders. Aequus collaborates with Sandoz Canada, Inc. for the promotion of Vistitan, Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic drugs, and Medicom Healthcare Ltd. to focus on preservative-free therapies in ophthalmology. With a small team of 12 employees, Aequus operates primarily in the Canadian market, seeking to expand its product offerings and partnerships.
What Products and Services Does AQSZF Offer?
- Develops and commercializes specialty pharmaceutical products.
- Focuses on therapeutic areas including neurology, ophthalmology, and transplantation.
- Markets Vistitan to reduce intraocular pressure in glaucoma patients.
- Offers Tacrolimus IR for the prevention of organ rejection.
- Provides Evolve dry eye products for dry eye disease and blepharitis.
- Develops extended-release oral tablets for the treatment of epilepsy.
- Develops cannabinoid-based therapeutics for neurological disorders.
How Does AQSZF Make Money?
- Develops and acquires rights to specialty pharmaceutical products.
- Commercializes products through direct sales and marketing efforts.
- Partners with other pharmaceutical companies for distribution and promotion.
- Generates revenue through product sales and licensing agreements.
What Industry Does AQSZF Operate In?
Aequus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and stringent regulatory requirements. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. Companies like Aequus focus on niche therapeutic areas to differentiate themselves. The industry is also influenced by pricing pressures, generic drug penetration, and the need for continuous innovation. Aequus's collaborations and focus on specific therapeutic areas position it to capitalize on market trends.
Who Are AQSZF's Key Customers?
- Patients with glaucoma and ocular hypertension.
- Patients undergoing organ transplantation.
- Patients with dry eye disease and blepharitis.
- Patients with epilepsy and other neurological disorders.
F-Score 3/9Financial Health
Aequus Pharmaceuticals Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Quarterly Financial Performance: Aequus Pharmaceuticals Inc.
Revenue for Aequus Pharmaceuticals Inc. came in at $252K during Q3 2025, a 15.4% improvement versus the preceding quarter. The company recorded net income of $370K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AQSZF averaged $-0.00 in diluted EPS.
AQSZF Valuation & Market Position
With a 146K market cap, Aequus Pharmaceuticals Inc. sits in the micro-cap segment of the market. Relative to its peer group, AQSZF's quantitative score of 59/100 is roughly in line with the peer average of 66/100.
ROE 9%Key Financial Metrics
Return on equity for Aequus Pharmaceuticals Inc. stands at 9.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -99.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Aequus Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Douglas Glen Janzen. AQSZF has traded publicly since 2015.
AQSZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Aequus's recent focus on strategic partnerships suggests a potential expansion of their product reach, hinting at future revenue opportunities.
- Insider buying activity, if present, could signal confidence in the company's long-term prospects, potentially influencing positive market perception.
- Positive community sentiment often reflects optimism about upcoming catalysts, such as regulatory approvals or product launches, which can drive short-term gains.
- The company's commitment to addressing unmet medical needs, reflected in community discussions, positions them favorably in a market increasingly focused on specialized treatments.
Bear Case
- Limited market awareness, echoed in subdued community chatter, may hinder the stock's ability to attract significant investment.
- Concerns about Aequus's ability to compete with larger pharmaceutical players, voiced within the community, could weigh on investor sentiment.
- Dependence on a small portfolio of products, as perceived by some traders, introduces vulnerability to market shifts and competitive pressures.
- Negative sentiment surrounding regulatory hurdles or clinical trial outcomes, if highlighted in recent discussions, might dampen enthusiasm for the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $251,754 | $370,483 | $0.0028 |
| Q2 2025 | $218,220 | -$163,909 | -$0.0012 |
| Q1 2025 | $226,545 | -$645,101 | -$0.0049 |
| Q4 2024 | $221,949 | -$217,811 | -$0.0016 |
Based on FMP financials and quantitative analysis
AQSZF Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 9, 2020
AQSZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AQSZF.
Price Targets
Wall Street price target analysis for AQSZF.
AQSZF MoonshotScore
What does this score mean?
The MoonshotScore rates AQSZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Douglas Glen Janzen
CEO
Douglas Glen Janzen serves as the CEO of Aequus Pharmaceuticals Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and business development. He has held various leadership positions in pharmaceutical companies, contributing to product launches, market access strategies, and partnership development. His expertise spans across multiple therapeutic areas, including neurology and ophthalmology. Janzen's experience positions him to lead Aequus in its growth and expansion efforts.
Track Record: Under Douglas Glen Janzen's leadership, Aequus Pharmaceuticals has focused on expanding its product portfolio and strengthening its strategic partnerships. Key milestones include the commercialization of Vistitan and the expansion of the Evolve dry eye product line. Janzen has also overseen the advancement of the company's development pipeline, including the progress of extended-release anti-epileptic drugs and cannabinoid-based therapeutics. His strategic decisions have aimed to position Aequus for sustainable growth in the specialty pharmaceutical market.
AQSZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aequus Pharmaceuticals Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the potential for lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: Lack of transparency due to minimal reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Potential for significant price swings due to limited trading activity.
- Regulatory Scrutiny: Increased risk of regulatory action due to non-compliance with reporting standards.
- Information Asymmetry: Limited access to reliable information compared to companies on major exchanges.
- Verify the company's financial statements and audit reports.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Analyze the company's cash flow and debt levels.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business Operations: Aequus Pharmaceuticals has been in operation since 2013.
- Product Portfolio: The company has a portfolio of marketed products and a development pipeline.
- Strategic Partnerships: Aequus has collaborations with reputable pharmaceutical companies.
- Focus on Specific Therapeutic Areas: The company specializes in neurology, ophthalmology, and transplantation.
- CEO Leadership: Douglas Glen Janzen has experience in the pharmaceutical industry.
Aequus Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered
What does Aequus Pharmaceuticals Inc. do?
Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company that develops and commercializes drugs in the therapeutic areas of neurology, ophthalmology, and transplantation. The company markets products like Vistitan for glaucoma and Evolve dry eye products. Aequus also has a development pipeline that includes extended-release anti-epileptic drugs and cannabinoid-based therapeutics for neurological disorders. The company focuses on addressing unmet medical needs through innovative products and strategic partnerships.
What do analysts say about AQSZF stock?
As of March 16, 2026, there is no readily available analyst consensus on AQSZF stock due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-1.01) and profit margin (-71.5%) reflect the company's current financial challenges. Growth considerations include the successful development and commercialization of pipeline products and expansion of existing product sales. Investors should conduct independent research and consider the risks associated with investing in OTC-listed companies.
What are the main risks for AQSZF?
The main risks for Aequus Pharmaceuticals Inc. include clinical trial failures for its development-stage products, regulatory delays or rejections for new product approvals, and increased competition from larger pharmaceutical companies. The company's small market capitalization and negative profit margin also pose financial risks. Dependence on partnerships for distribution and commercialization adds another layer of risk. Investors should carefully consider these factors before investing in AQSZF.
What are the key factors to evaluate for AQSZF?
Aequus Pharmaceuticals Inc. (AQSZF) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does AQSZF data refresh on this page?
AQSZF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AQSZF's recent stock price performance?
Aequus Pharmaceuticals Inc. (AQSZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AQSZF overvalued or undervalued right now?
Valuing Aequus Pharmaceuticals Inc. (AQSZF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AQSZF?
Before investing in Aequus Pharmaceuticals Inc. (AQSZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights in the future.